Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Alligator Bioscience

0.42 SEK

+8.85 %

Less than 1K followers

ATORX

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+8.85 %
-26.62 %
-63.89 %
-63.65 %
-92.91 %
-92.92 %
-98.34 %
-99.53 %
-99.91 %

Alligator Bioscience is a research-based biotechnology company that uses patented technology to develop biological drug candidates in inflammation and cancer. The company is active in the former part of the drug development chain. Alligator Bioscience has a global technology platform and is active in a rapidly growing segment of the pharmaceutical market - protein drugs. The company was founded in 2001 and is headquartered in Lund, Sweden.

Read more
Market cap
275.5M SEK
Turnover
1.11M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
12.2.
2026

Annual report '25

6.5.
2026

General meeting '26

All
Webcasts
Press releases
ShowingAll content types
Regulatory press releaseyesterday

Alligator publishes supplement prospectus

Alligator Bioscience
Regulatory press releaseyesterday

Alligator Bioscience publishes financial calendar for 2026

Alligator Bioscience
Regulatory press release12/1/2025, 5:30 PM

Alligator Bioscience enters into additional subscription undertakings and top guarantee commitments for the upcoming rights issue

Alligator Bioscience

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Press release12/1/2025, 7:45 AM

Alligator Bioscience announces publication of REACtiVe-2 Phase 1 trial data in Nature Communications

Alligator Bioscience
Regulatory press release11/28/2025, 10:45 AM

Alligator Bioscience publishes prospectus in connection with rights issue

Alligator Bioscience
Regulatory press release11/25/2025, 10:45 AM

Bulletin from the extraordinary general meeting in Alligator Bioscience AB

Alligator Bioscience
Regulatory press release11/24/2025, 8:00 PM

Alligator Bioscience announces final terms of rights issue

Alligator Bioscience
Press release11/19/2025, 7:13 AM

BioStock: Video from Alligator Bioscience's presentation at BioStock Life Science Summit 2025

Alligator Bioscience
Press release11/5/2025, 10:00 AM

Alligator Bioscience presents new data on mitazalimab and ATOR-4066 at SITC 40th Anniversary Annual Meeting

Alligator Bioscience
Regulatory press release11/3/2025, 2:00 PM

Nomination Committee appointed in respect of AGM 2026 in Alligator Bioscience AB

Alligator Bioscience
Press release10/24/2025, 7:10 AM

Redeye: Alligator Bioscience (Q3 Review) - Rights Issue of up to SEK120m

Alligator Bioscience
Regulatory press release10/23/2025, 6:00 AM

Alligator Bioscience AB reports financial results for Q3 2025 and provides a business update

Alligator Bioscience
Regulatory press release10/22/2025, 9:55 PM

Notice of extraordinary general meeting in Alligator Bioscience AB

Alligator Bioscience
Regulatory press release10/22/2025, 9:05 PM

Alligator Bioscience carries out a rights issue of units of approximately SEK 120 million and raises bridge loans

Alligator Bioscience
Press release10/21/2025, 8:30 AM

Alligator Bioscience granted US patent covering ATOR-4066 bispecific antibody

Alligator Bioscience
Press release10/16/2025, 6:45 AM

Invitation to Alligator Bioscience's earnings call on 23 October 2025

Alligator Bioscience
Press release10/13/2025, 6:45 AM

REACtiVe-2 Phase 1 data featuring mitazalimab demonstrate immune activation in metastatic pancreatic cancer – to be presented at ESMO 2025

Alligator Bioscience
Press release10/8/2025, 6:45 AM

Alligator announces publication of OPTIMIZE-1 biomarker analysis in Cell Reports Medicine supporting mitazalimab and mFOLFIRINOX in metastatic pancreatic cancer

Alligator Bioscience
Press release10/6/2025, 1:00 PM

Alligator Bioscience announces acceptance of two abstracts at SITC 40th Anniversary Annual Meeting

Alligator Bioscience
Regulatory press release9/30/2025, 1:00 PM

Change in number of shares and votes in Alligator Bioscience AB

Alligator Bioscience
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.